Longeveron Inc
longeveron.comWhat Do They Do?
Develops laromestrocel, an investigational cell therapy for patients with pediatric heart conditions, Alzheimer’s disease and aging-related frailty.
10-K for FY2025, filed Mar 17, 2026
How Do They Make Money?
Grant revenue is earned as grant requirements are met, and Bahamas Registry participants pay a fee to take part. Manufacturing customers pay for agreed work when it is complete; customers reserving suites or storage pay fixed monthly fees.
10-K for FY2025, filed Mar 17, 2026When appropriate funding opportunities arise, we routinely apply for grant funding to support our ongoing research and since 2016 we have…View ↗
As of December 2025, we have completed five U.S. clinical studies of laromestrocel: ELPIS I Phase 1 (HLHS), Phase 1 and "CLEAR MIND Trial"…View ↗
For contract manufacturing revenue, the Company considers the performance obligation met when the contractual obligation and/or statement…View ↗
-
10-K for FY2025, filed Mar 17, 2026
FY2025 revenue by product or service ↗
$1.2M
-
10-K for FY2025, filed Mar 17, 2026
$1.2M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Clinical trial revenue
|
80%
FY2022: 77%
|
Clinical trial revenue, FY2025
$954K Sources
|
|
|
Contract manufacturing lease revenue
Recurring
|
1.9% |
Contract manufacturing lease revenue, FY2025
$23K Sources
|
Recurring |
|
Contract manufacturing revenue
Sold outright
10-K for FY2025, filed Mar 17, 2026 |
19% |
Contract manufacturing revenue, FY2025
$222K Sources
|
Sold outright |
Who Are Their Customers?
Eligible participants pay a fee to take part in the Bahamas Registry Trial at private clinics; manufacturing and development customers engage through contracts that can include reserved suites and storage, and research funders provide grants.
10-K for FY2025, filed Mar 17, 2026As of December 2025, we have completed five U.S. clinical studies of laromestrocel: ELPIS I Phase 1 (HLHS), Phase 1 and "CLEAR MIND Trial"…View ↗
For contract manufacturing revenue, the Company considers the performance obligation met when the contractual obligation and/or statement…View ↗
When appropriate funding opportunities arise, we routinely apply for grant funding to support our ongoing research and since 2016 we have…View ↗
Do Revenues Turn Into Profits?
No. It lost $22.7M in FY2025.
10-K for FY2025, filed Mar 17, 2026
−$23.3MView ↗
10-K for FY2025, filed Mar 17, 2026
−$22.7MView ↗
10-K for FY2025, filed Mar 17, 2026
−$18.9MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 12, 2026
−$6.1MView ↗
- ▲ +21% (Loss)
- vs −$5M in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 12, 2026
Open tableView ↗
-
Aug 19, 2026
Longeveron appointed Nirav Jhaveri as CFO
He succeeded Marie Washburn, who returned to her former controller role.
Sources
8-K, filed Aug 19, 2026
Longeveron Inc. (the “Company”) has appointed Nirav S. Jhaveri to serve as Chief Financial Officer, principal financial officer and…View ↗
-
Jul 6, 2026
Marie Washburn became CFO after Lisa Locklear stepped down
Locklear left to pursue board opportunities and other professional and personal interests.
Sources
8-K, filed Jul 6, 2026
(c) As previously disclosed, on June 1, 2026, Lisa Locklear, Chief Financial Officer of Longeveron Inc. (the “Company”), provided notice to…View ↗
Shrinking. Revenue fell 8% in 4 years, from $1.3M in FY2021 to $1.2M in FY2025, about 2% a year.
Commercial manufacturing
Commercial production would move to a third party, while the Miami facility remains for clinical supply and early-stage work; the older report described plans to expand in-house commercial-scale manufacturing.
10-K for FY2022, filed Mar 14, 2023 10-K for FY2025, filed Mar 17, 2026
Added indication
The latest report adds pediatric dilated cardiomyopathy as an indication for laromestrocel; the older report described HLHS, aging-related frailty and Alzheimer’s disease as its pipeline indications.
10-K for FY2022, filed Mar 14, 2023 10-K for FY2025, filed Mar 17, 2026We are currently pursuing three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Aging-related Frailty, and Alzheimer’s…View ↗
Frailty program
Aging-related frailty moved from a planned Japanese clinical study to registry trials in The Bahamas after the Japan study was discontinued.
10-K for FY2022, filed Mar 14, 2023 10-K for FY2025, filed Mar 17, 2026Improvement of the quality of life for the aging population is one of the strategic directions of the Company. Life expectancy has…View ↗
Who Do They Compete With?
Competes with BioCardia, BlueRock Therapeutics, BrainStorm Cell Therapeutics, CellProthera, CorestemChemon, Cynata Therapeutics, Healios, Kadimastem, Medipost, Mesoblast, SanBio, and Stemedica Cell Technologies
10-K for FY2025, filed Mar 17, 2026Company Corporate Headquarters Clinical stage pipeline indications BioCardia USA Ischemic heart failure; Chronic Myocardial Ischemia…View ↗
Loading...
